T he effects of thiazolidinediones on cardiac function are controversial in humans with type 2 diabetes (T2DM) and in animals. Given the high prevalence and prognostic relevance of diastolic myocardial dysfunction in T2DM, we tested the hypothesis that by reducing oxidative stress rosiglitazone, but not glimepiride, may improve diastolic function.
Introduction
The effect of thiazolidinediones (TZDs) on cardiac function in patients with type 2 diabetes mellitus (T2DM) is under debate. Thiazolidinediones improve diabetic cardiomyopathy in animal models, [1] [2] [3] whereas their use in humans has been associated with fluid retention and congestive heart failure. [4] [5] [6] [7] [8] Among the first manifestations of cardiac abnormalities in diabetic patients are impairments of diastolic function, endothelial function and coronary flow reserve; all of these are not assessed routinely in clinical practice, but may improve if treated appropriately. [9] [10] [11] [12] [13] Interestingly, these myocardial abnormalities are found not only in patients with established diabetes but also in those with impaired glucose tolerance and insulin resistance. 14, 15 Indeed, insulin resistance is regarded as a cardiovascular risk factor long before the onset of overt T2DM. 16, 17 Most of the mechanisms involved relate to metabolic abnormalities, endothelial dysfunction, oxidative stress and release of inflammatory cytokines. [17] [18] [19] [20] In animals, thiazolidinediones have been shown to improve cardiac contractile function directly or indirectly by enhancing insulin sensitivity and reducing inflammation and oxidative stress. [1] [2] [3] 19 The action of thiazolidinediones on diastolic myocardial function in relation to these factors has not yet been demonstrated in man, however.
Given the high occurrence of diastolic myocardial dysfunction in patients with T2DM and its prognostic relevance, [20] [21] [22] we tested the hypothesis that the thiazolidinedione rosiglitazone, versus the sulfonylurea glimepiride, may improve diastolic myocardial function in these patients by simultaneously reducing oxidative stress and/or inflammation. Accordingly, the primary objective was to evaluate the change of diastolic myocardial function, measured as early diastolic myocardial velocity by pulsed tissue Doppler, after 16 weeks of oral treatment with rosiglitazone compared with glimepiride in patients with type 2 diabetes but without overt heart disease.
Methods

Study protocol
This pilot randomised cross-over single centre study investigated 12 metformin-treated T2DM patients before and after additional treatment with 8 mg rosiglitazone or 3 mg glimepiride. Metformin and all previous medications were continued throughout the study, including the fourweek wash-out period after the first study drug. Cardiac ultrasound and blood collections were performed with the patient in the fasting state at baseline and at week 16 of each therapy regimen. The treatment order of the study medication was determined by randomisation: six patients started with glimepiride. Patients were unaware of the potential differences of the study drugs on echocardiographic parameters. Analyses of data were carried out by a cardiologist who was blinded to the patients' clinical data.
Patients
Patients were selected based on the following inclusion criteria: T2DM of relative short duration, taking metformin monotherapy, both sexes, age 35-75 years, body mass index (BMI) 25-35 kg/m 2 , glycosylated haemoglobin (HbA 1C ) 6.5-9.0%, no major complications of macrovascular disease, normal systolic left ventricular (LV) function by 2-dimensional echocardiography, blood pressure normal or < 140/85 mmHg if treated, cholesterol and triglyceride levels < 250 mg/dL (6.5 and 2.8 mmol/L, respectively), no signs of microvascular complications and no albuminuria. Exclusion criteria were: atrial fibrillation, ischaemic heart disease (excluded by coronary angiography, stress echo or nuclear scintigraphy), severe left ventricular hypertrophy (septal thickness > 14 mm), history or signs of heart failure, hepatic and/or renal insufficiency (creatinine > 1.5 mg/dL). Thirteen patients were randomised but one patient withdrew consent from rosiglitazone treatment because of peripheral oedema. Accordingly, 12 patients were available for analysis.
The Ethical Committee of the Bayerische Ärztekammer, München, approved the study protocol. All participants gave their written informed consent to the study, which was designed in accordance with the Declaration of Helsinki.
Ultrasound investigations Doppler echocardiography
The ultrasound studies were performed with a commercially available system (ALOKA SSD-5500, Tokyo, Japan) equipped with tissue Doppler imaging and a 2.5 MHz transducer. Cross-sectional 2-dimensional and M-mode echocardiography were used to measure left ventricular dimensions and fractional shortening in the parasternal long axis and the left atrial longitudinal dimension in the apical 4-chamber view. Pulsed wave Doppler of the transmitral inflow was used to assess E and A velocities, the traditional parameters of global left ventricular diastolic function.
Tissue Doppler was applied as described previously. 22 In short, the regional myocardial velocities were averaged during three consecutive cycles in the basal septal, anterior septal, anterior, lateral, posterior and inferior walls for assessment of peak systolic velocity (S'), early diastolic velocity (E') and late diastolic velocity (A'). Global left ventricular function was taken as the mean value of these six regions with respect to systole, early and late diastole and left ventricular filling pressure calculated as E/E'. 23 
Biochemistry
Fasting serum glucose, serum insulin and lipid profile, glycosylated haemoglobin A 1C (HbA 1C ), leukocyte count and high-sensitivity C-reactive protein (hsCRP) were determined according to routine methods at the Department of Clinical Chemistry (Teaching Hospital Bogenhausen, Germany). Insulin resistance was calculated by the homeostatic model of assessment (HOMA-IR), as previously described. 24 Plasma malondialdehyde (MDA), interleukin-6 and adiponectin were assessed at the Department of Clinical Chemistry (VU University Medical Center). MDA was determined by high-performance liquid chromatography with fluorescence detection after reaction with thiobarbituric acid, as described previously. 25 The within-run and between-run variations were 3.5% and 8.7%, respectively. Interleukin-6 was measured by sandwich enzyme immunoassay (Quantikine High Sensitivity; R&D Systems, Oxon, UK). The intra-and interassay coefficients of variation were < 12%. Adiponectin was measured by radioimmunoassay (Linco Research, St Charles, MO, US). The within-run and between-run variations were 6.2% and 9.3%, respectively. Statistical analysis According to previous results, it is possible to detect changes in diastolic myocardial velocity of 1 cm/second with a twosided one-sample t-test with 80% power, standard deviation (SD) of 0.9 and α of 0.05 in eight patients. 26 Statistical analysis was performed using the SPSS version 12.0 software package (SPSS, Inc., Chicago, IL, US). Data are expressed as mean + SD when normally distributed, as median (interquartile range) or log-transformed (MDA, interleukin-6) if non-normally distributed. Student's t-test or nonparametric tests were used for group comparisons, where appropriate. Changes from baseline to end point measurements (Δ) were calculated. To detect determinants of ΔE', variables that were associated with ΔE' at p<0.1 in univariate linear regression analysis were entered into multivariate regression models. Significance level was set at p<0.05.
Results
Patient characteristics, averaged from data at the first visit, are listed in table 1. Rosiglitazone was well tolerated by all 12 patients. No patient showed clinical signs or symptoms of fluid retention. One patient on glimepiride reported hypoglycaemic episodes.
Metabolism, oxidative stress and inflammation
Rosiglitazone and glimepiride induced the same non-significant improvement in HbA 1C (table 2) . Furthermore, rosiglitazone, but not glimepiride, significantly reduced fasting blood glucose (table 2) and post-meal glucose two hours after a standardised carbohydrate (48 g) meal (196+57 to 161+51 mg/dL, p<0.01), whereas the concomitant improvement in insulin sensitivity just missed statistical significance (p=0.054). Finally, rosiglitazone significantly lowered the oxidative stress marker MDA, lowered hsCRP and increased adiponectin, whereas the reduction in interleukin-6 was of borderline significance (table 2). None of these effects were observed with glimepiride.
Myocardial function
With rosiglitazone, there was a significant improvement of E' ORIGINAL ARTICLE
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DIABETES AND VASCULAR DISEASE RESEARCH figure 1 ), paralleled by an increase in fractional shortening (p=0.034) and a non-significant increase in mitral inflow velocity E (p=0.054). No significant changes in these parameters were observed with glimepiride. All other cardiac dimensions and haemodynamic parameters, including blood pressure, heart rate and left ventricular filling pressure, remained unchanged with both treatment regimens (table 3) .
Determinants of diastolic functional changes
Univariate analyses In the rosiglitazone group, improvement in E' was significantly associated with ΔMDA (r=-0.677, p=0.022; figure 2), followed by BMI at baseline (r=0.590, p=0.044), whereas the association with ΔHbA 1C was of borderline significance (r=-0.519, p=0.084). No significant associations were observed between ΔE' and Δinsulin resistance or changes in inflammatory markers. With glimepiride, ΔE' was only significantly correlated with baseline HbA 1C (r=0.639, p=0.025), whereas the association with ΔHbA 1C missed significance (r=-0.569, p=0.053).
In the pooled data, ΔE' was correlated with ΔHbA 1C (r= -0.484, p=0.017), whereas the associations of ΔE' with Δ interleukin-6 and ΔMDA were of borderline significance (data not shown). Both in the total and separate analyses, ΔE' was not associated with age, gender, nor with baseline or Δfasting glucose, blood pressure, lipids or markers of inflammation (data not shown).
Multivariate analyses Multivariate analysis was separately performed for rosiglitazone and glimepiride to address the determinants of ΔE'. ΔE' was set as the dependent, with MDA changes and BMI entered as independent variables, and subsequent corrections for parameters that correlated with E' at p<0.1 in the univariate analysis. To test the robustness of the association, additional adjustments were made for variables that were modified by therapy and/or those that could potentially have 
Discussion
This study extends animal data by showing improvement of myocardial diastolic function in asymptomatic metformintreated patients with T2DM after 16 weeks of therapy with rosiglitazone, with a concomitant reduction in oxidative stress and inflammation. Rosiglitazone-induced lowering of oxidative stress appeared to be an independent determinant of improvement in cardiac function. No such effects were observed with glimepiride, in spite of its similar effect on HbA 1C . Importantly, no therapy-related changes were observed in haemodynamic or cardiac parameters known to ameliorate diastolic myocardial function, indicating that another mechanism may underlie the observed functional improvement in these T2DM patients, who were in relatively good glycaemic control and who did not have overt cardiovascular disease or diabetic complications.
Quantification of diastolic dysfunction by tissue Doppler
Pulsed tissue Doppler imaging is gaining recognition as a robust and reproducible ultrasound technique which compensates for the deficiencies of traditional echocardiographic parameters in the assessment of diastolic and systolic dysfunction of normal-sized hearts. [27] [28] [29] It effectively quantitates left ventricular function by measuring both diastolic and systolic myocardial velocity of long-axis motion in cm/second as E' and S', respectively. By applying this technique, predominantly diastolic myocardial dysfunction has been demonstrated in patients with type 2 diabetes at rest and during stress 22 and also in young and fit type 1 diabetes patients, each in comparison to age-matched non-diabetic controls. 26 The mean baseline value E' of 8.2+1.5 cm/second diastolic myocardial velocity in the present data is consistent with earlier data showing values of 8.8+1.7 cm/second in individuals with type 2 diabetes without coronary artery disease vs. 10.1+1.7 in age matched non-diabetic controls, 30 and similar also to an analogue study with values of 8.5+1.7 vs. 9.5+1.7 cm/second. 22 The rosiglitazone-induced augmentation of diastolic myocardial velocity to 8.9+1.2 cm/second observed here does not bring diastolic function to the levels of non-diabetic controls, however.
Mechanisms of oxidative stress in diabetic cardiomyopathy
Left ventricular diastolic dysfunction is regarded as the first stage of diabetic cardiomyopathy and is more severe if hypertension is also present.
14 In diabetes, diastolic dysfunction, due to impaired left ventricular relaxation and stiffening, is attributed to altered energy metabolism, microvascular dysfunction and damage, remodelling and formation of advanced glycation end products (AGE). 19, 20, 31, 32 Furthermore, diabetic cardiomyopathy has been associated with a proinflammatory state and, in particular, with increased oxidative stress. 32, 33 Both of these mechanisms are strongly linked to the complex pathophysiology of type 2 diabetes. In type 2 diabetes, insulin resistance elevates circulating levels of non-esterified fatty acids by increasing lipolysis from adipose tissue stores, whereas progressive β-cell dysfunction leads to hyperglycaemia. The ensuing excessive substrate supply induces high fluxes through the β-oxidation and the TCA cycles, thus increasing the delivery of reducing equivalents to the mitochondrial electron transport chain, and leading to increased production of reactive oxygen species (ROS) in various tissues such as endothelial cells and cardiomyocytes. 20 Thus, oxidative stress may impair cardiac function by direct effects on cardiomyocytes and, indirectly, by causing endothelial dysfunction and altered myocardial perfusion. In experimental diabetes, mitochondrial damage and dysfunction mediated by reactive oxygen species led to cardiomyocyte apoptosis and abnormal cardiac remodelling, with altered structure and function compatible with diabetic cardiomyopathy. Increased reactive oxygen species may also contribute to mitochondrial uncoupling, which could impair energy metabolism in the diabetic heart. 20 Also, reactive oxygen species may interfere with insulin signalling, thus contributing to the grave sequelae of insulin resistance in diabetes. 34 Finally, oxidative stress may reduce the bioavailability of nitric oxide, which is known to play a role in cardiac perfusion, function and structure. 35, 36 In animal models, diabetic cardiomyopathy as well as heart failure are associated with increased oxidative stress. 20, 36 ORIGINAL ARTICLE
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DIABETES AND VASCULAR DISEASE RESEARCH Oxidative stress reduction in the study patients To the best of our knowledge, the present data demonstrate for the first time that rosiglitazone therapy can improve diastolic function in patients with well controlled diabetes, without heart failure and coronary heart disease. These data confirm studies in animal models of diabetes, which have previously shown that TZD therapy improves cardiac function, [1] [2] [3] paralleled by a decrease in oxidative stress. 3 In other studies, a thiazolidinedione-related decrease in oxidative stress has been found in association with concomitant improvement in metabolic control but without changes in glycaemia as observed in the present data. 1, 37 In our patients, rosiglitazone decreased fasting glucose levels and insulin resistance -yet significantly associated factors for the decrease in oxidative stress were not observed after the 16-week intervention. Inasmuch as MDA levels represent hyperglycaemia-induced lipid peroxidation, the mechanism underlying rosiglitazoneinduced MDA reduction may be through up-regulation of anti-oxidant defence even when, on average, blood glucose remained unchanged. 20, 38 The present data do not allow us to determine how much the observed changes of MDA may have also been related to a reduction of free fatty acids and/or of postprandial hyperglycaemia. Of interest, the glycaemic response during glimepiride therapy was not associated with oxidative stress reduction or improved diastolic function.
Cardiac function and thiazolidinediones
Rosiglitazone reduced inflammation, improved insulin sensitivity and increased circulating levels of adiponectin in our patients, who did not have ischaemic heart disease. However, these beneficial effects were not significantly correlated with cardiac functional improvement. This lack of association may be due to a type II error, or it may be that oxidative stress makes a stronger contribution to cardiac dysfunction in uncomplicated diabetes than inflammation and insulin resistance which may have a greater adverse impact on cardiac function in the additional presence of myocardial ischaemia or heart failure. [39] [40] [41] Indeed, in studies in animal models of diabetes, thiazolidinediones improved ischaemia/ reperfusion-induced myocardial injury and dysfunction by inhibition of inflammation and amelioration of cardiac insulin resistance. 40, 41 Instead, BMI and the treatment-related changes in insulin sensitivity and interleukin-6 levels were significantly interrelated. These findings confirm the reported insulin-sensitising and antiinflammatory actions of thiazolidinediones on adipocytes. 42 Adiponectin may reduce inflammation, enhance endothelial function and modulate metabolism, the latter by activating AMP kinase leading to increased β-oxidation and glucose uptake. 43 Recent data show that adiponectin has beneficial effects on cardiac function during ischaemia and reperfusion, 44 but its role in diabetic cardiomyopathy remains to be shown.
The use of thiazolidinediones in T2DM has been controversial due to their tendency to cause fluid retention and increase the risk of congestive heart failure in susceptible patients, as observed in the intervention trials DREAM, PROactive and ADOPT. 6, 7, 45 Patients with more severe congestive heart failure (NYHA class > II), those with ischaemic heart disease and patients receiving concomitant insulin therapy are presumably at greatest risk. Other authors, however, have reported no excessive risk, 5, 46 or have even found benefit in specific patient populations. 4, 47 Indeed, FrankStarling's mechanism describes improved LV function by increased preload in the normally ejecting ventricle. In our patients, rosiglitazone-induced relevant volume overload was excluded on the basis of unchanged atrial and ventricular diameters. Similarly, in patients with no overt heart disease, six months of thiazolidinedione therapy has been observed to improve left ventricular diastolic function. 48, 49 In these latter studies, however, no additional mechanism was addressed that could explain these effects. Given the known cardiovascular risk of insulin resistance and its associated cardiometabolic abnormalities including oxidative stress, their improvement by TZD therapy appears particularly promising for preventing diabetic cardiomyopathy in the early stage of diabetic disease and should be evaluated accordingly. Identifying the patient characteristics likely to benefit from the increased insulin sensitivity induced by rosiglitazone therapy in combination with a low risk for heart failure may help to clarify some of the conflicting data with regards to myocardial infarction and heart failure revealed in recent meta-analyses 50, 51 which included patients at varying degrees of risk for cardiovascular events.
Limitations
The relatively small sample size may be regarded as a limitation; however, the study population was relatively homogeneous due to strict inclusion criteria. Although such a strict selection limits generalisation of the data, the demonstration of significant associations in this small study group supports the relevance of the findings. The associations found do not reflect causal relationships. We observed a relatively modest effect of both therapies on glycaemic control due to the low HbA 1C at baseline in our patients, since the efficacy of many blood-glucose lowering compounds is proportional to baseline HbA 1C . 42, 52 Finally, the design of the present study did not allow us to evaluate other mechanisms that may underlie diastolic functional changes in T2DM, including the ORIGINAL ARTICLE
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DIABETES AND VASCULAR DISEASE RESEARCH , for the respective models i.e. Model 1, with changes of early diastolic velocity (ΔE') as dependent, changes in malondialdehyde (ΔMDA) as independent variable; in model 2, ΔMDA and body mass index (BMI) at baseline are independent variables; in model 3, ΔMDA, BMI at baseline and ΔHbA 1C are independent variables; in Model 4, ΔMDA, BMI at baseline and ΔHOMA-IR are independent variables; in model 5, ΔMDA, BMI at baseline and Δinterleukin-6 are independent variables. In models 6 (a-g), possible confounders of the association of E' and ΔMDA are separately entered, Beta and (95% CI) for the association of ΔE' and ΔMDA are listed. *p, level of significance for the association between E' and the separate components of Models 1-5 or for ΔMDA after the adjustments indicated (models 6 (a-g)); †p, level of significance of the model. reduced availability of energy from mitochondrial high energy phosphate metabolism, 31 that may hamper the functioning of the sarcoplasmic reticulum-calcium ATPase pump (SERCA) and impair the energy-demanding early phase of diastolic function, or the role of AGE-related stiffening of blood vessels and myocardium that may compromise late diastolic function. With regards to the unchanged values of the mitral A wave velocity, however, this latter mechanism does not appear relevant in the present study in patients with uncomplicated, well-controlled T2DM of relatively short duration.
In summary, rosiglitazone therapy improved diastolic myocardial function in association with decreases in oxidative stress in asymptomatic patients with well controlled, uncomplicated T2DM without coronary artery disease or heart failure. None of these changes nor associations were observed after glimepiride therapy, in spite of identical HbA 1C reduction. Given the current lack of evidence-based therapies for diastolic dysfunction in general and in view of the high occurrence and poor prognosis of diastolic dysfunction in T2DM in particular, large-sized studies should be set up to establish the long-term beneficial cardiac effects of thiazolidinediones and help to identify the specific patient populations that may benefit from these compounds.
